Key statistics
On Thursday, Supernus Pharmaceuticals Inc (SUPN:NMQ) closed at 32.13, -9.34% below its 52-week high of 35.44, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.26 |
---|---|
High | 32.26 |
Low | 31.78 |
Bid | 12.86 |
Offer | 51.08 |
Previous close | 31.84 |
Average volume | 420.02k |
---|---|
Shares outstanding | 55.11m |
Free float | 52.33m |
P/E (TTM) | 363.75 |
Market cap | 1.77bn USD |
EPS (TTM) | 0.0883 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Announces Second Quarter 2024 Financial Results
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
- Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
- Supernus Announces First Quarter 2024 Financial Results
More ▼